- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of April 1
The Center for Biosimilars® recaps the top news for the week of April 1, 2019.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 1.
Number 5: A new consensus report calls the nocebo effect underrecognized in the area of biosimilars and says that more research is needed on this important topic.
Number 4: Stakeholders testified before a House of Representatives subcommittee about the impact of the rising costs of insulin.
Number 3: A head-to-head study, published in The Lancet, has produced data that may help allay gastroenterologists’ concerns about using CT-P13 in Corhn disease.
Number 2: Sandoz announced that it has resubmitted its Biologics License Application for its pegfilgrastim biosimilar referencing Neulasta.
Number 1: Yet another class action lawsuit has been filed against AbbVie, maker of Humira. This time, Baltimore, Maryland, is suing both AbbVie and Amgen for delayed biosimilar competition.
Finally, last week, our e-newsletter asked whether you agree with the FDA’s decision to require 4-letter suffixes only for newly approved biologics and biosimlars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
